Milestone Pharmaceuticals Gets Notice of Allowance for US Patent on Etripamil Nasal Spray

MT Newswires Live
02-19

Milestone Pharmaceuticals (MIST) said Wednesday it received notice of allowance from the US Patent and Trademark Office on a patent for etripamil nasal spray, the company's investigational product to manage paroxysmal supraventricular tachycardia.

The patent covers the repeat dose regimen used in a phase 3 study that assessed the nasal spray in paroxysmal supraventricular tachycardia and was proposed for the package insert as part of the nasal spray's new drug application that is under review by the US Food and Drug Administration, the company said.

The repeat dose regimen directs the patient to take a second 70-milligram dose of the nasal spray if the person is still seeing symptoms from their paroxysmal supraventricular tachycardia episode 10 minutes after the initial dose, Milestone said.

The issuance of the notice of allowance potentially extends the company's intellectual property protection for the nasal spray in the US until July 2042, Milestone said.

The company said it's still advancing commercial preparations to back the expected launch of the nasal spray, with the brand name Cardamyst, in mid-2025.

Price: 2.20, Change: -0.01, Percent Change: -0.45

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10